Gilead Sciences Inc. and Genesis Therapeutics Inc. have entered into a strategic collaboration to discover and develop novel small-molecule therapies across multiple targets.
Mid-Atlantic Biotherapeutics Inc. and Accelero Biostructures have entered into a research collaboration to identify novel USP30 inhibitors for neurological disorders and other indications.
Bayer AG and Nextrna Therapeutics Inc. have entered into a collaboration and license agreement to develop small-molecule therapeutics targeting long noncoding RNAs (lncRNAs) in oncology. Under the agreement, Bayer gains access to Nextrna’s differentiated approach to inhibit the function of lncRNAs by disrupting the interaction between lncRNAs and RNA-binding proteins (RBPs) with small molecules.
